Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ACAM2000 Smallpox Vaccine · 1 trial · 1 indication
The neutralizing antibody response titers were determined by the Plaque-Reduction Neutralization Test (PRNT50)
| Arm | Type | Description |
|---|---|---|
| Group 1: ACAM2000 | EXPERIMENTAL | Participants will receive dose 1 of the ACAM2000 smallpox vaccine |
| Group 2: ACAM2000 | EXPERIMENTAL | Participants will receive dose 2 of the ACAM2000 smallpox vaccine |
| Group 3: ACAM2000 | EXPERIMENTAL | Participants will receive dose 3 of the ACAM2000 smallpox vaccine |
| Group 4: ACAM2000 | EXPERIMENTAL | Participants will receive dose 4 of the ACAM2000 smallpox vaccine |
| Group 5: Dryvax® | ACTIVE_COMPARATOR | Participants will receive dose 1 of Dryvax® smallpox vaccine. |
| Name | Type | Description |
|---|---|---|
| ACAM2000 Smallpox Vaccine | BIOLOGICAL | Group 1 dose: 1.0x10-8th PFU/ml, Group 2 dose: 2.0x10-7th PFU/ml, Group 3 dose: 1.0x10-7th PFU/ml, Group 4 dose: 5.0x10-6th PFUL/ml |
| Vaccinia virus (calf lymph) smallpox vaccine: Dryvax® | BIOLOGICAL | Group 5 dose: 1.0x10-8th PFU/ml |
Inclusion criteria: * have a history of previous smallpox vaccination greater than 10 years previous to the date of screening and presence of a vaccination scar. * females must not be pregnant, lactating and must agree to use an effective form of birth control for the 30 days following vaccination ...
ACAM2000 Smallpox Vaccine is a vaccine developed for protection against smallpox, an infectious disease. It is being developed by Emergent BioSolutions Inc. under the ticker EBS. The vaccine has been studied in a Phase 2 clinical trial in previously vaccinated adults.
ACAM2000 Smallpox Vaccine is intended for use against smallpox, a serious infectious disease. Its clinical development has focused on evaluating the vaccine in adults who were previously vaccinated against smallpox, with the goal of supporting protection against the disease.
ACAM2000 Smallpox Vaccine is developed by Emergent BioSolutions Inc., which trades under the ticker EBS. The company is the sponsor of the clinical program evaluating the vaccine for smallpox.
ACAM2000 Smallpox Vaccine is in Phase 2 development. One Phase 2 trial has been completed, and no trials are currently active. The program has not been described as approved, so the vaccine remains in clinical development for smallpox.
ACAM2000 Smallpox Vaccine has been studied in one completed Phase 2 trial, NCT00053482, titled Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults. The trial enrolled 357 participants in the United States, was randomized, double blind, and used an active control.